105 related articles for article (PubMed ID: 34467246)
1. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A
Cancer Immunol Immunother; 2017 Mar; 66(3):367-378. PubMed ID: 27933426
[TBL] [Abstract][Full Text] [Related]
2. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.
Ugel S; Facciponte JG; De Sanctis F; Facciabene A
Cancer Immunol Immunother; 2015 Oct; 64(10):1339-48. PubMed ID: 26267042
[TBL] [Abstract][Full Text] [Related]
3. Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy.
Yuan X; Yang M; Chen X; Zhang X; Sukhadia S; Musolino N; Bao H; Chen T; Xu C; Wang Q; Santoro S; Ricklin D; Hu J; Lin R; Yang W; Li Z; Qin W; Zhao A; Scholler N; Coukos G
Cancer Immunol Immunother; 2018 Feb; 67(2):329-339. PubMed ID: 29313073
[TBL] [Abstract][Full Text] [Related]
4. A membrane protein display platform for receptor interactome discovery.
Cao S; Peterson SM; Müller S; Reichelt M; McRoberts Amador C; Martinez-Martin N
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34531301
[TBL] [Abstract][Full Text] [Related]
5. Atypical TNF-TNFR superfamily binding interface in the GITR-GITRL complex for T cell activation.
Zhao M; Fu L; Chai Y; Sun M; Li Y; Wang S; Qi J; Zeng B; Kang L; Gao GF; Tan S
Cell Rep; 2021 Sep; 36(12):109734. PubMed ID: 34551288
[TBL] [Abstract][Full Text] [Related]
6. Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.
Warwas KM; Meyer M; Gonçalves M; Moldenhauer G; Bulbuc N; Knabe S; Luckner-Minden C; Ziegelmeier C; Heussel CP; Zörnig I; Jäger D; Momburg F
Front Immunol; 2021; 12():719116. PubMed ID: 34484225
[TBL] [Abstract][Full Text] [Related]
7. Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera FG; Ronet C; Ochoa de Olza M; Barras D; Crespo I; Andreatta M; Corria-Osorio J; Spill A; Benedetti F; Genolet R; Orcurto A; Imbimbo M; Ghisoni E; Navarro Rodrigo B; Berthold DR; Sarivalasis A; Zaman K; Duran R; Dromain C; Prior J; Schaefer N; Bourhis J; Dimopoulou G; Tsourti Z; Messemaker M; Smith T; Warren SE; Foukas P; Rusakiewicz S; Pittet MJ; Zimmermann S; Sempoux C; Dafni U; Harari A; Kandalaft LE; Carmona SJ; Dangaj Laniti D; Irving M; Coukos G
Cancer Discov; 2022 Jan; 12(1):108-133. PubMed ID: 34479871
[TBL] [Abstract][Full Text] [Related]
8. Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens.
Hwang MS; Miller MS; Thirawatananond P; Douglass J; Wright KM; Hsiue EH; Mog BJ; Aytenfisu TY; Murphy MB; Aitana Azurmendi P; Skora AD; Pearlman AH; Paul S; DiNapoli SR; Konig MF; Bettegowda C; Pardoll DM; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S; Gabelli SB
Nat Commun; 2021 Sep; 12(1):5271. PubMed ID: 34489470
[TBL] [Abstract][Full Text] [Related]
9. Group XIV C-type lectins: emerging targets in tumor angiogenesis.
Yee EJ; Vigil I; Sun Y; Torphy RJ; Schulick RD; Zhu Y
Angiogenesis; 2024 May; 27(2):173-192. PubMed ID: 38468017
[TBL] [Abstract][Full Text] [Related]
10. Targeting the activated microenvironment with endosialin (CD248)-directed CAR-T cells ablates perivascular cells to impair tumor growth and metastasis.
Ash SL; Orha R; Mole H; Dinesh-Kumar M; Lee SP; Turrell FK; Isacke CM
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38413223
[TBL] [Abstract][Full Text] [Related]
11. Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy.
Meo C; de Nigris F
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339244
[TBL] [Abstract][Full Text] [Related]
12. Endosialin in Cancer: Expression Patterns, Mechanistic Insights, and Therapeutic Approaches.
Lu S; Gan L; Lu T; Zhang K; Zhang J; Wu X; Han D; Xu C; Liu S; Yang F; Qin W; Wen W
Theranostics; 2024; 14(1):379-391. PubMed ID: 38164138
[TBL] [Abstract][Full Text] [Related]
13. Application Progress of the Single Domain Antibody in Medicine.
Tang H; Gao Y; Han J
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835588
[TBL] [Abstract][Full Text] [Related]
14. The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy.
Guizhen Z; Guanchang J; Liwen L; Huifen W; Zhigang R; Ranran S; Zujiang Y
Front Endocrinol (Lausanne); 2022; 13():918869. PubMed ID: 36093115
[TBL] [Abstract][Full Text] [Related]
15. Latest developments in the pathobiology of Ewing sarcoma.
Karlina I; Schroeder BA; Kirgizov K; Romantsova O; Istranov AL; Nedorubov A; Timashev P; Ulasov I
J Bone Oncol; 2022 Aug; 35():100440. PubMed ID: 35855933
[TBL] [Abstract][Full Text] [Related]
16. Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
Fierle JK; Brioschi M; de Tiani M; Wetterwald L; Atsaves V; Abram-Saliba J; Petrova TV; Coukos G; Dunn SM
Cell Rep Med; 2021 Aug; 2(8):100362. PubMed ID: 34467246
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.
D'Onofrio A; Gano L; Melo R; Mendes F; Oliveira MC; Denoël T; Schaefer N; Viertl D; Fierle J; Coukos G; Dunn S; Prior JO; Paulo A
Eur J Pharm Biopharm; 2021 Jan; 158():233-244. PubMed ID: 33271301
[TBL] [Abstract][Full Text] [Related]
18. Tumour endothelial marker 1/endosialin-mediated targeting of human sarcoma.
Guo Y; Hu J; Wang Y; Peng X; Min J; Wang J; Matthaiou E; Cheng Y; Sun K; Tong X; Fan Y; Zhang PJ; Kandalaft LE; Irving M; Coukos G; Li C
Eur J Cancer; 2018 Feb; 90():111-121. PubMed ID: 29304474
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
